501892-99-5

Basic information

• Product Name: 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID
• Synonyms: 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID
• CAS NO: 501892-99-5
• Molecular Formula: C10H8O3
• Molecular Weight: 176.17
• Mol File: 501892-99-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 346 °C at 760 mmHg
• Flash Point: 163 °C
• Appearance: /
• Density: 1.303 g/cm³
• Vapor Pressure: 2.25E-05mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID(501892-99-5)
• EPA Substance Registry System: 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID(501892-99-5)

Safety Data

• Hazardous Substances Data: 501892-99-5(Hazardous Substances Data)

Usage

General Description

3-Methylbenzofuran-5-carboxylic acid is a chemical compound with the molecular formula C11H8O3. It is a derivative of benzofuran with a carboxylic acid group attached to the 5-position and a methyl group attached to the 3-position. It is commonly used in the synthesis of pharmaceuticals due to its versatile reactivity and potential medicinal properties. 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID is also known for its aromatic properties and is often used as a building block in organic synthesis. It is important to handle this compound with caution as it may pose health hazards if not handled properly.

InChI:InChI=1/C10H8O3/c1-6-5-13-9-3-2-7(10(11)12)4-8(6)9/h2-5H,1H3,(H,11,12)

Upstream product

• 57009-12-8 methyl 3-acetyl-4-hydroxybenzoate 
• 96-32-2 bromoacetic acid methyl ester 
• 16357-40-7 3-acetyl-4-hydroxybenzoic acid 
• 501892-97-3 methyl 4-(allyloxy)-3-iodobenzoate 
• 15126-06-4 methyl 3-iodo-4-hydroxybenzoate 
• 501892-98-4 methyl 3-methylbenzofuran-5-carboxylate 

Downstream Products

• 1379278-90-6 3-chlorobenzofuran-5-carboxylaic acid 

Relevant articles and documents

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.